Acadia Pharmaceuticals | ACAD - 贸易债权人



金融业
股票价格
USD
资产
USD 1.74B
现金及等价物
USD 956.47M
销售成本
USD 28.32M
流动资产
USD 1.22B
流动负债
USD 361.44M
债务
USD 50.79M
EBIT
USD 37.84M
EBITDA
USD -1.62M
员工
653
EPS每股收益
USD 0.18
股本和储备
USD 1.31B
销售毛利
USD 279.64M
债务利息支出
USD 0
利息收入
USD 8.06M
贷款资金
USD 0
市值
USD 4.95B
净收入
USD 31.5M
营业费用
USD 270.12M
营业利润
USD 37.84M
普通股股本
USD 171.09M
PE价格收益
11.33
税前利润
USD 46.47M
销售收入
USD 307.96M
销售和管理费用
USD 148.57M
股票
USD 108.67M
贸易债权人
USD 44.57M
应收帐款人
USD 166.33M


贸易债权人 更改 日
Acadia Pharmaceuticals USD 44.57M 32.32M 2026-06
ALKERMES USD 142.86M 40.5M 2026-06
Alnylam Pharmaceuticals USD 108.02M 18.61M 2026-06
Biogen USD 403.9M 45.4M 2026-06
BioMarin Pharmaceutical USD 913.67M 120.52M 2026-06
Bristol-Myers Squibb USD 4.16B 76M 2026-06
Cara Therapeutics USD 4.62M 1.4M 2026-03
Corcept Therapeutics USD 14.91M 18.4M 2026-06
Cytokinetics USD 20.51M 4.2M 2026-06
Eisai JPY 87.53B 11.64B 2026-06
Eli Lilly USD 6.11B 1.08B 2026-06
Incyte USD 1.39B 1.16B 2026-06
J&J USD 9.22B 1.24B 2026-06
Moderna USD 167M 6M 2026-06
Neurocrine Biosciences USD 691.3M 145.8M 2026-03
Pfizer USD 4.58B 75M 2026-06
Prothena USD 1.94M 2.36M 2026-06
PTC Therapeutics USD 40.45M 14.96M 2026-06
Sarepta Therapeutics USD 50.98M 19.39M 2026-06
Ultragenyx Pharmaceutical USD 39M 3M 2026-06
Vanda Pharmaceuticals USD 39.09M 33.28M 2024-12
Vertex Pharmaceuticals USD 3.61B 135M 2026-06